☆ 4.8 Article

A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell-Based Cancer Immunotherapy

ADVANCED MATERIALS (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Multidisciplinary

Supramolecular Filament Hydrogel as a Universal Immunomodulator Carrier for Immunotherapy Combinations

Feihu Wang et al.

Summary: A peptide-based supramolecular filament hydrogel was designed and synthesized as a carrier for localized delivery of three immunomodulating agents. The hydrogel acted as a depot for sustained release of the immunotherapeutic agents, resulting in enhanced antitumor activities and reduced side effects. Combination therapy using the hydrogel led to complete regression of tumors and elicited a systemic antitumor immunity. This hydrogel offers a simple and generalizable strategy for local delivery of immunomodulators, improving treatment outcomes.

ACS NANO (2023)

Add to Collection

Article Multidisciplinary Sciences

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence

Hong -Wei An et al.

Summary: Alpha-interferon was found to reduce the bladder cancer recurrence rate to 22%. In comparison, the recurrence rates were 89% and 78% for doxycycline and BCG treatment, respectively, which are currently used in clinic. Mechanistic studies showed that bsGP enhances the infiltration of CD8+ T cells into tumor cells by reducing the matrix microenvironment barrier.

SCIENCE ADVANCES (2023)

Add to Collection

Article Chemistry, Multidisciplinary

In Situ Self-Assembly of Bispecific Peptide for Cancer Immunotherapy

Man-Di Wang et al.

Summary: This study reports a programmable peptide molecule that enables specific and efficient assembly by binding to targeting receptor proteins. By designing different peptide sequences and receptor bindings, it is possible to promote oligomerization and functional regulation of protein complexes.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition

Chang-ling Gu et al.

Summary: The study developed a bispecific antibody targeting PD1 and HER2, showing high affinities and potent antitumor activities in vitro and in vivo. The BsAb also demonstrated both HER2 and PD1 blockade activities and was effective in killing HER2-positive tumor cells through antibody-dependent cellular cytotoxicity.

ACTA PHARMACOLOGICA SINICA (2022)

Add to Collection

Article Immunology

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L. Banta et al.

Summary: Dual blockade of PD-1 and TIGIT is effective in enhancing anti-tumor CD8(+) T cell responses, with concurrent blockade of CD28 and CD226 being necessary for optimal therapeutic effect.

IMMUNITY (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Eunsil Sung et al.

Summary: This study introduces ABL501, a bispecific antibody targeting LAG-3 and PD-L1, which enhances anti-tumor efficacy by modulating immune cell responses against tumors.

MOLECULAR THERAPY (2022)

Add to Collection

Article Chemistry, Multidisciplinary

A bispecific nanomodulator to potentiate photothermal cancer immunotherapy

Lei Zhou et al.

Summary: A bispecific nanomodulator is developed to trigger photothermal therapy and dual-block PD-L1 and IDO-1 pathways for boosting effective antitumor immunity.

NANO TODAY (2022)

Add to Collection

Article Multidisciplinary Sciences

A vaccine targeting resistant tumours by dual T cell plus NK cell attack

Soumya Badrinath et al.

Summary: A cancer vaccine that induces a coordinated attack by diverse T cell and NK cell populations is reported. The vaccine targets MICA/B stress proteins expressed by human cancers and enhances immune recognition by inhibiting proteolytic shedding, increasing antigen presentation, and augmenting cytotoxic function. The vaccine also shows efficacy in inhibiting metastasis and protecting against escape mutations.

NATURE (2022)

Add to Collection

Article Nanoscience & Nanotechnology

Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy

Yifei Lu et al.

Summary: Compared to hematological tumors, solid tumors have a lower response to immunotherapies. In this study, the authors propose a strategy to enhance the effectiveness of immunotherapies for solid tumors by decorating the cell membrane with a protein that promotes phagocytosis of cancer cells.

NATURE NANOTECHNOLOGY (2022)

Add to Collection

Article Oncology

Therapeutic bispecific antibodies against intracellular tumor antigens

Guanghui Xu et al.

Summary: Bispecific antibodies (BsAbs) have shown promise as immunotherapy strategies, but have been limited to targeting cell surface antigens. However, recent attention has been focused on BsAbs that target intracellular oncoproteins, broadening the scope of tumor antigen targeting and improving the effectiveness of antibody-based therapies.

CANCER LETTERS (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment

Lu Zhang et al.

Summary: This study reports a programmable tumor cells/T-eff cells bispecific nano-immunoengager that can enhance the efficacy of immune checkpoint blockade therapy by improving T cell infiltration and modulating the immunosuppressive tumor microenvironment.

NANO LETTERS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

Camila Ordonez-Reyes et al.

Summary: Immunotherapy, particularly bispecific antibodies, has revolutionized cancer treatment by redirecting the immune response towards specific antigens and tumor locations. This article discusses the design and function of bispecific antibodies, their challenges, and their current state-of-the-art in treating hematological and solid malignancies, as well as future perspectives.

PHARMACEUTICS (2022)

Add to Collection

Article Engineering, Biomedical

Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment

Jiali Zhang et al.

Summary: Excessive CD4(+ )T helper (Th)-B-cell interactions and loss of Treg homeostasis are crucial to the pathogenesis of systemic lupus erythematosus (SLE). In this study, RAP-encapsulated ICOS/CD40L bispecific nanoparticles were designed to selectively target SLE Th cells and inhibit Th-B-cell reciprocal activation, with the sustained release of RAP further promoting the expansion of Treg cells and alleviating SLE progression without obvious toxicity.

BIOMATERIALS (2022)

Add to Collection

Article Hematology

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Lijun Zhao et al.

Summary: This study developed a novel approach for enhancing antitumor efficacy and overcoming immune escape by designing a CD19/CD22/CD3 trispecific antibody (tsAb). The optimized tsAb showed superior ability in inducing T-cell-specific cytotoxicity and cytokine production against CD19+ and/or CD22+ tumor cells compared to other tsAb formats. It also demonstrated significantly enhanced anti-tumor efficacy and the ability to overcome immune escape.

BLOOD (2022)

Add to Collection

Article Multidisciplinary Sciences

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Zhenwei Zhong et al.

Summary: The combination therapy of anti-PD-L1 and anti-TIGIT has shown synergistic efficacy in cancer immunotherapy. Constructing bispecific antibodies targeting PD-L1 and TIGIT can provide new mechanisms of action.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Bispecific Aptamer-Based Recognition-then- Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy

Yang Sun et al.

Summary: This study reported a bispecific aptamer that improved T-cell immune response and induced a potent immunological effect against tumors through a recognition-then-conjugation strategy.

ACS NANO (2022)

Add to Collection

Review Biochemical Research Methods

The Role of Cell Organelles in Rheumatoid Arthritis with Focus on Exosomes

Zahra Payandeh et al.

Summary: Auto-immune diseases affect a significant portion of the population in wealthy countries, with Rheumatoid Arthritis being a common autoimmune disease. This condition can lead to synovial inflammation and joint injury, and exosomes have emerged as potential therapeutic vectors for treating such diseases.

BIOLOGICAL PROCEDURES ONLINE (2021)

Add to Collection

Article Engineering, Biomedical

Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer

Feihu Wang et al.

Summary: The localized chemoimmunotherapy system using aSP hydrogel enables sustained release of bioactive camptothecin and aPD1 into the tumor microenvironment, leading to robust infiltration of tumor-associated T cells and a response to immune checkpoint blockade. This approach provokes a long-term and systemic anticancer T cell immune response, resulting in tumor regression and inhibition of recurrence and metastasis.

BIOMATERIALS (2021)

Add to Collection

Review Nanoscience & Nanotechnology

Nanomaterials for T-cell cancer immunotherapy

Ningqiang Gong et al.

Summary: T-cell-based immunotherapies show promise in treating cancer, but face challenges such as insufficient expansion of transferred T cells and inefficient trafficking into tumors. Nanomaterials offer a solution to enhance T-cell therapy by overcoming physical barriers and modulating tumor microenvironments.

NATURE NANOTECHNOLOGY (2021)

Add to Collection

Article Oncology

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

Li Li et al.

Summary: The study developed a new strategy by combining conventional targeted therapy with immune checkpoint blockade using a tumor-targeting bispecific antibody. This antibody not only directly inhibits tumor growth through EGFR inhibition but also activates T cell anti-tumor immunity by blocking the interaction between PD1 and PDL1.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Bi-specific macrophage nano-engager for cancer immunotherapy

Yu Zhao et al.

Summary: The bi-specific macrophage nano-engager (BiME) enhances the recognition and phagocytosis of tumor cells by macrophages, achieving effective tumor-associated antigen (TAA) uptake and presentation to activate antitumor responses. BiME converts tumor cells into an in situ vaccine, triggering robust T cell-dependent antitumor responses, and could potentially be a universal strategy for enhancing antitumor immunity against a broad range of solid tumors.

NANO TODAY (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy

Cheng-Tao Jiang et al.

Summary: The researchers developed a versatile antibody immobilization platform by conjugating antibodies onto nanoparticles, which effectively enhanced antitumor immune responses mediated by T cells, natural killer cells, and macrophages. This strategy shows promise in improving the efficacy of immunotherapy.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Yunqian Qiao et al.

Summary: IBI319, a CD137/PD-1 bispecific antibody, overcomes the limitations of CD137 agonists in cancer immunotherapy by restricting T cell activation to the tumor microenvironment through coupling CD137 activation with PD-1 crosslinking, resulting in effective tumor control and reduced liver toxicity.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Engineering, Biomedical

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

Longchao Liu et al.

Summary: A bispecific antibody targeting T-cell receptor CD3 epsilon and immune checkpoint PD-L1 on dendritic cells rejuvenates tumor-specific CD8 T cells, leading to durable antitumor responses in murine models of cancer.

NATURE BIOMEDICAL ENGINEERING (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Selective Degradation of PD-L1 in Cancer Cells by Enzyme-Instructed Self-Assembly

Yuhan Wang et al.

Summary: A novel strategy utilizing self-assembly between ALP and PD-L1 to selectively degrade PD-L1 in tumor cells is reported. This strategy selectively encapsulates PD-L1 in nanomaterials for further degradation, showing potential for inhibiting tumor growth in animal models.

ADVANCED FUNCTIONAL MATERIALS (2021)

Add to Collection

Article Oncology

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

William Freed-Pastor et al.

Summary: The CD155/TIGIT axis can be utilized for immune evasion in chronic viral infections and cancers like pancreatic adenocarcinoma. Studies have shown that a significant portion of PDAC patients have predicted high-affinity MHC class I-restricted neoepitopes, and modulation of the CD155/TIGIT axis can promote immune evasion in PDAC. In preclinical models, a combination immunotherapy targeting TIGIT/PD-1 plus CD40 agonism has shown promising anti-tumor responses.

CANCER CELL (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells

Kai-Ge Chen et al.

Summary: Innate immune cells play a crucial role in tumor surveillance and elimination through their spontaneous tumoricidal effects. Dual-functional super bispecific nano-antibodies can regulate the antitumor response of innate immune cells and establish a close physical connection between effector cells and tumor cells, enhancing innate antitumor immunity in vitro and in vivo.

NANO TODAY (2021)

Add to Collection

Article Cell Biology

Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors

Anli Zhang et al.

Summary: The study focused on utilizing a heterodimer combining an anti-CTLA-4 antibody and CD47 ligand SIRP alpha to enhance immunity against solid tumors by selectively depleting immunosuppressive T-reg cells in the TME. The results demonstrated the potential of modulating both eat me and do not eat me signals as an effective strategy for treating solid tumors.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

Anand Rotte et al.

Summary: Immune checkpoint blockers have improved survival chances in patients with metastatic cancer, but only a subset of patients respond to treatment. Inhibiting TIGIT has shown promise in pre-clinical and early clinical studies, but challenges remain in identifying beneficial patients and obtaining payer coverage.

BIOMEDICINES (2021)

Add to Collection

Review Engineering, Biomedical

Artificial Engineering of Immune Cells for Improved Immunotherapy

Chuxin Li et al.

Summary: Cell-based immunotherapy harnesses the innate advantages of immune cells to treat diseases like cancer and inflammatory diseases, with the potential for improved therapeutic efficacy and expanded function through the combination of cellular biology, nanotechnology, and material science. This review discusses recent advances in utilizing nanotechnology and materials to enhance the therapeutic functions of immune cells, as well as briefly summarizing strategies in engineered cell immunotherapy and potential trends in this field.

ADVANCED NANOBIOMED RESEARCH (2021)

Add to Collection

Review Immunology

TIGIT as an emerging immune checkpoint

H. Harjunpaa et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection

Article Chemistry, Multidisciplinary

A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy

Xiuman Zhou et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

Add to Collection

Article Oncology

A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma

Lin Yu et al.

CANCER BIOLOGY & THERAPY (2020)

Add to Collection

Review Cell Biology

Immune checkpoint signaling and cancer immunotherapy

Xing He et al.

CELL RESEARCH (2020)

Add to Collection

Article Multidisciplinary Sciences

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy

Feihu Wang et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

Linlin Ma et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)

Add to Collection

Article Cell Biology

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

Xiuman Zhou et al.

CELL COMMUNICATION AND SIGNALING (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide

Peiwei Yang et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Peak Fitting Applied to Fourier Transform Infrared and Raman Spectroscopic Analysis of Proteins

Azin Sadat et al.

APPLIED SCIENCES-BASEL (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy

Chen Bai et al.

NANOSCALE (2020)

Add to Collection

Article Chemistry, Multidisciplinary

A strong CD8+ T cell-stimulating supramolecular hydrogel

Xinxin Li et al.

NANOSCALE (2020)

Add to Collection

Review Immunology

Enhancing cancer immunotherapy with nanomedicine

Darrell J. Irvine et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Bispecific antibodies: a mechanistic review of the pipeline

Aran F. Labrijn et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Article Oncology

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Mathieu Grapin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Nanoscience & Nanotechnology

Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2

Christina L. Parker et al.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Delivery technologies for cancer immunotherapy

Rachel S. Riley et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Article Chemistry, Multidisciplinary

A supramolecular hydrogel to boost the production of antibodies for phosphorylated proteins

Youzhi Wang et al.

CHEMICAL COMMUNICATIONS (2019)

Add to Collection

Review Medicine, Research & Experimental

Peptide-based materials for cancer immunotherapy

Lu Zhang et al.

THERANOSTICS (2019)

Add to Collection

Article Chemistry, Multidisciplinary

Tandem Molecular Self-Assembly in Liver Cancer Cells

Jie Zhan et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)

Add to Collection

Article Chemistry, Multidisciplinary

Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy

Keman Cheng et al.

NANO LETTERS (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells

Alexander S. Cheung et al.

NATURE BIOTECHNOLOGY (2018)

Add to Collection

Review Chemistry, Multidisciplinary

Nanoscale delivery systems for cancer immunotherapy

Zejun Wang et al.

MATERIALS HORIZONS (2018)

Add to Collection

Review Oncology

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations

Judith A. Seidel et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection

Article Chemistry, Multidisciplinary

A Powerful CD8+ T-Cell Stimulating D-Tetra-Peptide Hydrogel as a Very Promising Vaccine Adjuvant

Zichao Luo et al.

ADVANCED MATERIALS (2017)

Add to Collection

Editorial Material Immunology

Introduction to checkpoint inhibitors and cancer immunotherapy INTRODUCTION

Arlene H. Sharpe

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Engineering Bifunctional Antibodies with Constant Region Fusion Architectures

Juanjuan Du et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation

John W. Hickey et al.

NANO LETTERS (2017)

Add to Collection

Article Nanoscience & Nanotechnology

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Hengfeng Yuan et al.

NATURE NANOTECHNOLOGY (2017)

Add to Collection

Review Immunology

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

Nicholas A. Manieri et al.

TRENDS IN IMMUNOLOGY (2017)

Add to Collection

Review Immunology

Regulation of Murine Natural Killer Cell Development

Wilford Goh et al.

FRONTIERS IN IMMUNOLOGY (2017)

Add to Collection

Article Oncology

Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions

Feng Xu et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth

Alyssa K. Kosmides et al.

ACS NANO (2017)

Add to Collection

Article Engineering, Biomedical

Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies

Christopher B. Howard et al.

ADVANCED HEALTHCARE MATERIALS (2016)

Add to Collection

Article Chemistry, Multidisciplinary

Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy

Hao-Nan Chang et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)

Add to Collection

Article Medicine, Research & Experimental

TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients

Joe-Marc Chauvin et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

Add to Collection

Review Oncology

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Jingjing Wu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection

Review Oncology

Peptide-based cancer therapy: Opportunity and challenge

Dongdong Wu et al.

CANCER LETTERS (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.